UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 15)
Evolving Systems, Inc.
(Name of Issuer)
Common Stock
(Title of Class of
Securities)
30049R209
(CUSIP Number)
Karen Singer
212 Vaccaro Drive
Cresskill, NJ 07626
(201) 750-0415
(Name, Address and
Telephone Number
of Person Authorized to Receive Notices
and Communications)
March 15. 2011
(Date of Event Which
Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to report this
acquisition that is the subject of this Schedule 13D, and is filing this Schedule because of Rule
13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box: o
*The remainder of this cover page shall be filled out for a reporting person’s initial filing
on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed”
for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject
to the liabilities of that section of the Act but shall be subject to all other provisions of the
Act.
This constitutes Amendment No. 15 (the “Amendment No. 15”) to the Statement on
Schedule 13D, filed on behalf of Karen Singer (“Ms. Singer”), dated February 28, 2008 (the
“Statement”), relating to the common stock (the “Common Stock”) of Evolving Systems, Inc., a
Delaware corporation (the “Issuer” or “Company”). Unless specifically amended or modified hereby,
the disclosure set forth in the Statement shall remain unchanged.
Item 4. Purpose of the Transaction.
Item 4 of the Statement is hereby amended by adding the following at the end thereof:
On November 26, 2010, Ms. Singer entered into a Confidentiality Agreement, in the
form filed as Exhibit 99.1 to the Schedule 13D filed on December 1, 2010 (the “November
Confidentiality Agreement”), by and among the Issuer and Ms. Singer. Effective March 15, 2011, the
November Confidentiality Agreement was amended to extend the period during which it remains
effective so that, as so amended, the November Confidentiality Agreement remains in effect until
April 15, 2011.
Except as described above in this Item 4 and herein, Ms. Singer does not currently have any
specific plans or proposals that relate to or would result in any of the actions or events
specified in clauses (a) through (j) of Item 4 of Schedule 13D. Ms. Singer reserves the right to
change plans and take any and all actions that Ms. Singer may deem appropriate to maximize the
value of her investments, including, among other things, purchasing or otherwise acquiring
additional securities of the Issuer, selling or otherwise disposing of any securities of the Issuer
beneficially owned by her, in each case in the open market or in privately negotiated transactions,
or formulating other plans or proposals regarding the Issuer or its securities to the extent deemed
advisable by Ms. Singer in light of her general investment policies, market conditions, subsequent
developments affecting the Issuer and the general business and future prospects of the Issuer. Ms.
Singer may take any other action with respect to the Issuer or any of the Issuer’s debt or equity
securities in any manner permitted by applicable law.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of
the Issuer
Item 4 of this Schedule 13D/A is incorporated herein by reference.
Item 7. Material to be Filed as Exhibits
Exhibit 99.1 Amendment to Confidentiality Agreement dated March 15, 2011.